drugset
Drugs / Autologous bone marrow mononuclear cell transplantation
last change Sep 2016 re-read 3 minutes ago

Autologous bone marrow mononuclear cell transplantation

Cell therapy

Developed for
limb-girdle muscular dystrophy · traumatic brain injury
Investigated by
Neurogen Brain and Spine Institute

Trials 2

today NCT02028104 · Ph 1 NCT02050776 · Ph 1
2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02028104 Jan 2010 → Apr 2016 traumatic brain injury Neurogen Brain and Spine Institute Withdrawn No outcome recorded
Phase 1 NCT02050776 Dec 2008 → Mar 2013 limb-girdle muscular dystrophy Neurogen Brain and Spine Institute Withdrawn No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Autologous bone marrow mononuclear cell transplantation ClinicalTrials.gov intervention name — accepted as the source's own label NCT02050776 ↗
1

NCT02028104 ↗
Modality Cell therapy “stem cell therapy” NCT02028104 ↗
Route Intrathecal “bone marrow derived mononuclear cells are administered intrathecally in traumatic brain injury patients” NCT02028104 ↗